相关实验视频
Updated: Jun 19, 2025
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
510
布雷克斯皮普拉用于与阿尔茨海默氏病引起的痴呆症相关的激动症
Daniel Lee1, Emily D Clark1, Inga M Antonsdottir2
1Alzheimer's Disease Care, Research and Education (AD-CARE), Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Journal of the American Medical Directors Association
|July 25, 2024
概括
布雷克西普拉是第一个批准用于阿尔茨海默氏症 (AD) 兴奋的药物. 临床试验表明,与安慰剂相比,它显著减少了动荡,尽管有潜在的副作用和死亡风险.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 神经精神症状 (NPS),特别是动荡,在阿尔茨海默病患者中很常见.
- 在AD痴呆症中,激动对患者和护理人员构成重大挑战.
研究的目的:
- 审查布雷克斯皮普拉在治疗阿尔茨海默病引起的痴呆症相关的动时的疗效和安全性.
- 讨论brexpiprazole的作用机制,剂量考虑和不良影响.
- 评估布雷克斯皮普拉在治疗阿尔茨海默氏病时的临床意义和治疗中的位置.
主要方法:
- 对AD激发中布雷克斯皮普拉的临床试验数据的审查.
- 分析布雷克斯皮普拉的药理概况,包括受体活性.
- 检查安全数据,包括不良反应和死亡率.
主要成果:
- 布雷克斯皮普拉 (2-3毫克/天) 在12周内与安慰剂相比,在激发得分 (科恩-曼斯菲尔德激发库存) 中显示出统计学上显著的减少.
- 药物一般耐受性良好,常见的副作用包括头,头痛和失眠.
- 与安慰剂相比,布雷克斯皮普拉与死亡率的增加有关,这与用于此指标的抗精神病药物共同存在的担忧.
结论:
- 布雷克西普拉是第一个FDA批准的药理疗法,用于阿尔茨海默氏症痴呆症的激发.
- 虽然有效,但考虑因素包括潜在的副作用,药物相互作用和增加的死亡风险.
- 布雷克斯皮普拉的批准可能为其他新型药物,如埃斯基塔洛普拉姆和德克斯特罗米多芬-布普罗铺平了道路.
相关概念视频
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
01:24Parkinson's Disease: Treatment
244
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
244
01:23Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
01:28Psychosis and Antipsychotic Drugs: Overview
216
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
216
01:26Psychosis: Goals of Pharmacotherapy
114
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
114
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
638
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
638